GLYC GlycoMimetics Inc
5,543
$0.3054
$0.0101
(3.20%)
| Watchers | 5,543 |
| 52-Wk Low | $0.27 |
| 52-Wk High | $3.53 |
| Market Cap | $19.68M |
| Volume | 7.12M |
| 52-Wk High | $3.53 |
| 52-Wk Low | $0.27 |
GlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares SinkBenzinga • 1 day ago
Get insights on GlycoMimetics Inc's Phase 3 study results for uproleselan in R/R AML patients. Explore survival rates, adverse events, and future analyses.
read more...
Share to Feed
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today announced topline...
GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access...
HC Wainwright restated their buy rating on shares of GlycoMimetics (NASDAQ:GLYC - Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a...
GlycoMimetics, Inc. (NASDAQ:GLYC - Free Report) - HC Wainwright issued their FY2026 EPS estimates for shares of GlycoMimetics in a report issued on Wednesday, March 27th. HC Wainwright analyst E...
This is a signal that GLYC's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX Research Report), GlycoMimetics...
Related Stocks: NAS:GLYC...
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript March 27, 2024
GlycoMimetics, Inc. isnt one of the 30 most popular stocks among hedge funds at the end of the third quarter...
GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its...